Ingeborg Mathiesen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ingeborg Mathiesen has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Arnfinn Sundsfjord
Research group for Host-Microbe Interactions, Department of Medical Biology, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromsø, Norway
1 shared publication - Barbara Juliane Holzknecht
Department of Clinical Medicine, University of Copenhagen, Blegdamsvej 3B, DK-2200 Copenhagen N, Denmark; Department of Clinical Microbiology, Copenhagen University Hospital - Herlev and Gentofte, Borgmester Ib Juuls Vej 1, DK-2730 Herlev, Denmark
1 shared publication - Bjørg Christina Haldorsen
Norwegian Centre for Detection of Antimicrobial Resistance, Department of Microbiology and Infection Control, University Hospital of North Norway, Tromsø, Norway
1 shared publication - Erika Matuschek
EUCAST Development Laboratory, Växjö, Sweden
1 shared publication Frode Skjold
Department of Pharmacy, UIT The Arctic University of Norway, Tromsø, Norway
1 shared publicationGunnar Kahlmeter
EUCAST Development Laboratory, Clinical Microbiology, Växjö Hospital, Växjö, Sweden
1 shared publication
Latest Publications
- Open Access
- 4 June 2026
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 45 (9) , 1-11
Performance of disk diffusion and MIC gradient tests in tigecycline susceptibility testing of enterococci: a Nordic multicentre study
Purpose Evaluating the performance of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) disk diffusion (DD) and minimum inhibitory concentration (MIC) gradient methods for tigecycline susceptibility testing of enterococci using broth microdilution (BMD) as the reference method. Methods All 83 Nordic clinical microbiology laboratories were invited to test a blinded collection of diverse whole genome sequenced Enterococcus faecalis (n = 10) and Enterococcus faecium (n = 10) strains using the EUCAST DD and gradient MIC methods (Etest or MTS). Results were compared to reference BMD MICs and genotype (presence/absence of known tigecycline resistance determinants). Categorical agreement (CA), essential agreement (EA), and bias were calculated according to international standards. Results Forty-four laboratories contributed to 880 EUCAST DD and 800 MIC gradient test observations. The EUCAST DD method demonstrated a CA of 97.3% when compared to reference MIC and 93.0% when compared to genotype. Gradient tests achieved an overall EA of 95.9% (Etest: 96.3%; MTS: 95.5%) and a CA of 96.3% when compared to reference MICs and 96.5% when compared to genotype. Both Etest and MTS exhibited acceptable bias (Etest: +21.8%; MTS: -19.1%). Conclusion The EUCAST DD method and gradient tests demonstrated acceptable performance in accordance with international standards. Errors were mainly related to borderline strains near the tigecycline breakpoint. Further research is required on tigecycline-resistant enterococci and the development of improved AST methods for categorisation of borderline strains.
- 4 June 2026
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 45 (9) , 1-11
Open AccessPerformance of disk diffusion and MIC gradient tests in tigecycline susceptibility testing of enterococci: a Nordic multicentre study
Purpose Evaluating the performance of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) disk diffusion (DD) and minimum inhibitory concentration (MIC) gradient methods for tigecycline susceptibility testing of enterococci using broth microdilution (BMD) as the reference method. Methods All 83 Nordic clinical microbiology laboratories were invited to test a blinded collection of diverse whole genome sequenced Enterococcus faecalis (n = 10) and Enterococcus faecium (n = 10) strains using the EUCAST DD and gradient MIC methods (Etest or MTS). Results were compared to reference BMD MICs and genotype (presence/absence of known tigecycline resistance determinants). Categorical agreement (CA), essential agreement (EA), and bias were calculated according to international standards. Results Forty-four laboratories contributed to 880 EUCAST DD and 800 MIC gradient test observations. The EUCAST DD method demonstrated a CA of 97.3% when compared to reference MIC and 93.0% when compared to genotype. Gradient tests achieved an overall EA of 95.9% (Etest: 96.3%; MTS: 95.5%) and a CA of 96.3% when compared to reference MICs and 96.5% when compared to genotype. Both Etest and MTS exhibited acceptable bias (Etest: +21.8%; MTS: -19.1%). Conclusion The EUCAST DD method and gradient tests demonstrated acceptable performance in accordance with international standards. Errors were mainly related to borderline strains near the tigecycline breakpoint. Further research is required on tigecycline-resistant enterococci and the development of improved AST methods for categorisation of borderline strains.